Navigation Links
Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
Date:2/19/2008

ing for 2006.

Total operating expenses increased to $33.8 million for the year ended December 31, 2007, from $16.1 million for the same period in 2006.

Medivation ended 2007 with $43.3 million in cash and equivalents, plus a remaining capacity of $78.8 million under its committed equity line of credit facility. The Company expects total operating expenses in 2008 to increase significantly beyond 2007 levels, due primarily to further expansion of Dimebon and MDV3100 development, including the upcoming confirmatory pivotal Phase 3 trial of Dimebon in AD and the expanded dosing groups in the ongoing Phase 1-2 trial of MDV3100 in HRPC.

2008 Corporate Milestones

"In 2008, we plan to begin multiple AD clinical trials for Dimebon, including our confirmatory pivotal Phase 3 trial. We also look forward to presenting a steady stream of data across all of our programs in 2008 -- including top-line results from our ongoing Phase 2 trials in Huntington's disease and hormone-refractory prostate cancer," continued Dr. Hung.

During 2008 Medivation intends to:

-- Initiate a second, confirmatory pivotal Phase 3 trial of Dimebon in AD

in the second quarter with the goal of completing the trial and

applying for U.S. and European marketing approval in 2010.

-- Conduct multiple clinical trials of Dimebon in AD for marketing and

reimbursement purposes and to provide a safety database of

approximately 1,500 patients as part of its marketing application. In

the second quarter of 2008, the Company plans to begin the first of

these trials -- a 20 patient Phase 1 trial to evaluate the safety and

tolerability of Dimebon when given to AD patients who are also taking

Aricept(R), the leading AD treatment on the market.

-- Complete the ongoing Phase 2 study of Dimebon in Huntington's disease

in the second quarter.

-- Begin global Phase 3 clinical studie
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
3. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
4. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
5. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
6. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
7. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
8. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
9. Escalon(R) Reports Second Quarter Fiscal 2008 Results
10. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
11. Eklin Medical Reports Record Revenues for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015 ... developing novel biological drugs to treat cancer, viral ... announce the appointment of Christina Coughlin ... responsible for providing medical and regulatory leadership to ... Dr. Coughlin has extensive experience in ...
(Date:3/31/2015)... VANCOUVER , March 31, 2015  /PRNewswire/ - ESSA ... today that it has filed with the Food and ... Drug ("IND") application related to the Company,s proposed clinical ... the IND application is required in order for ESSA ... The IND application is a complete ...
(Date:3/31/2015)... March 31, 2015 Pittcon 2015, the ... Spectroscopy, ended on March 12, in New Orleans with ... million as estimated by the New Orleans Convention and ... 14,200 conferees and exhibitor personnel. Those who attended ... conferee number. For the third year, the co-location of ...
(Date:3/31/2015)... 2015   Mapi expands Pharmacovigilance and ... and global Risk Management strength with the expanded ... acquisition . Pharmacovigilance and ... global team that includes physicians, pharmacists, and numerous ... in navigating complex safety requirements throughout the product ...
Breaking Biology Technology:Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 4ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 2ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 3ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 4Pittcon 2015 Hits the Big Easy in a Big Way 2Pittcon 2015 Hits the Big Easy in a Big Way 3Pittcon 2015 Hits the Big Easy in a Big Way 4Mapi expands Pharmacovigilance and Risk Management capabilities 2Mapi expands Pharmacovigilance and Risk Management capabilities 3
... Readies R & D facilities for Ap3ana, CTI,s ... Cell Therapeutics, Inc. (CTI),(Nasdaq: CTIC ) announced ... President and COO of a Tyr Pharma and ... the Novartis Research,Foundation, has been named President of ...
... BioPharma,Corp. (TSX; FSE: HBP) today announced that it has ... 6,800,000 units at $1.68 per,unit, for gross proceeds totaling ... and one-half of one common share,purchase warrant, with each ... subject to adjustment, one common share at a price,of ...
... Investors, WILMINGTON, Del., Oct. 2 Speaking ... General Manager John Ranieri,said the company,s plans to ... on track and making significant technical progress toward ... feedstocks,economically into biofuels., "Biobutanol and cellulosic ethanol ...
Cached Biology Technology:Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4Helix Biopharma Closes $11.4 Million Private Placement 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
(Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
(Date:3/2/2015)... Lithuania , March 2, 2015   Neurotechnology ... technologies, today introduced the SentiGaze Software Development Kit ... to create applications that use off-the-shelf webcams to track ... user gazes at a monitor. Heatmaps can be used ... the effectiveness of online advertising. The SDK can also ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... obesity increasing, school administrators and public health officials are ... a study published in the November/December 2008 issue of ... researchers found that reduction or elimination of SSB from ... adolescents. Working with four schools in Maine ...
... to be averted, atmospheric carbon dioxide (CO2) must be reduced below ... in Open Atmospheric Science Journal by a ... and France. The authors, who include two Yale ... which civilization developed, an optimum CO2 level would be less than ...
... Ph.D., of the New York City Department of Health and ... be one of our body,s main protections against damage from ... of Low Radiation , Hayes explains that calcitriol, the active ... and could be used as a safe protective agent before ...
Cached Biology News:Revised theory suggests carbon dioxide levels already in danger zone 2Could vitamin D save us from radiation? 2